Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

July 22, 2008; 71 (4) Articles

Topiramate in pregnancy

Preliminary experience from the UK Epilepsy and Pregnancy Register

S. Hunt, A. Russell, W. H. Smithson, L. Parsons, I. Robertson, R. Waddell, B. Irwin, P. J. Morrison, J. Morrow, J. Craig
First published July 21, 2008, DOI: https://doi.org/10.1212/01.wnl.0000318293.28278.33
S. Hunt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Russell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. H. Smithson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Parsons
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Robertson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Waddell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Irwin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. J. Morrison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Morrow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Craig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Topiramate in pregnancy
Preliminary experience from the UK Epilepsy and Pregnancy Register
S. Hunt, A. Russell, W. H. Smithson, L. Parsons, I. Robertson, R. Waddell, B. Irwin, P. J. Morrison, J. Morrow, J. Craig
Neurology Jul 2008, 71 (4) 272-276; DOI: 10.1212/01.wnl.0000318293.28278.33

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1534

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objectives: Topiramate (Topamax®) is licensed to be used, either in monotherapy or as adjunctive treatment, for generalized tonic clonic seizures or partial seizures with or without secondary generalization and for prevention of migraine. The safety of topiramate in human pregnancy is largely unknown. Here we report on our experience of pregnancies exposed to topiramate.

Methods: This study is part of a prospective, observational, registration and follow-up study. Suitable cases are women with epilepsy who become pregnant while taking topiramate either singly or along with other antiepileptic drugs (AEDs), and who are referred before outcome of the pregnancy is known. The main outcome measure is the major congenital malformation (MCM) rate. Secondary outcomes include risk of specific MCM, minor malformation rate, birthweight, and gestational age at delivery.

Results: Full outcome data are available on 203 pregnancies. Of these, 178 resulted in live birth; 16 had an MCM (9.0%; 95% CI 5.6% to 14.1%). Three MCMs were observed in 70 monotherapy exposures (4.8%; 95% CI 1.7% to 13.3%) and 13 in cases exposed to topiramate as part of a polytherapy regimen (11.2%; 95% CI 6.7% to 18.2%). Four of the MCMs were oral clefts (2.2%; 95% CI 0.9% to 5.6%). Four cases of hypospadias were reported (5.1%; 95% CI 0.2% to 10.1%) among 78 known live male births of which two were classified as major malformations.

Conclusions: The number of outcomes of human pregnancies exposed to topiramate is low, but the major congenital malformation rate for topiramate polytherapy raises some concerns. Overall, the rate of oral clefts observed was 11 times the background rate. Although the present data provide new information, they should be interpreted with caution due to the sample size and wide confidence intervals.

Glossary

AED=
antiepileptic drug;
MCM=
major congenital malformation;
SGA=
small for gestational age.

It is widely accepted that prenatal exposure to antiepileptic drugs (AEDs) increases the risk of major congenital malformations (MCM) from the background risk of 1% to 2%1–3 to between 4% and 9%.3–5 However, except for lamotrigine,5,6 levetiracetam,7 and oxcarbazepine,8 information is limited on the other newly available AEDs (vigabatrin, gabapentin, topiramate, tiagabine, pregabalin, and zonisamide).

Topiramate is licensed for use both in monotherapy and as adjunctive treatment for generalized tonic clonic seizures or partial seizures with or without secondary generalization. During 2004 it was also licensed by the Food and Drug Administration for prophylaxis of migraine.

Topiramate has been shown to be teratogenic in mice, rats, and rabbits.9 In mice doses as low as 0.2 times the maximum recommended human dose (400 mg/m2) were associated with an increased frequency of (primarily) craniofacial defects.

Safety data for topiramate in human pregnancy are limited. A company sponsored abstract reported outcomes for 75 pregnancies exposed to topiramate.10 Of 29 monotherapy exposures two malformations (micrognathia, phimosis) were noted. Of the remaining 46 pregnancies that had also been exposed to at least one other AED seven infants had a malformation (cleft palate, cleft lip, tetralogy of Fallot, hand malformation, ureteral stenosis, pyloric stenosis, and one infant with cleft lip and palate, fixed extension of upper limb, bilateral radial deviation of hands, brachydactyly, and hydrocephalus).

METHODS

The UK Epilepsy and Pregnancy Register is a prospective pregnancy register set up to determine the relative safety of all AEDs taken in pregnancy. Here we report our results for first-trimester exposures to topiramate, through August 31, 2007.

Suitable cases are women with epilepsy who became pregnant while taking topiramate, either singly or along with other AEDs, and who were referred before the outcome of the pregnancy was known. The main outcome measure was the MCM rate. Cases where any prenatal test (fetal ultrasound, blood test) had shown an abnormality and cases resulting in a pregnancy loss (induced abortion, spontaneous abortion, stillbirth) in which an abnormality had been identified before referral to the register had been made were excluded.

A major seizure is defined as a tonic-clonic seizure. A minor or other seizure denotes seizures without convulsive activity.

Outcome data were collected at 3 months after the expected date of delivery by sending the patient’s general practitioner a standardized questionnaire for completion.

An MCM was defined as an abnormality of an essential embryonic structure requiring significant treatment and present at birth or discovered during the first 6 weeks of life. Disorders not conforming to this definition were assigned as minor malformations based on the definitions and lists of disorders in the EUROCAT registry.11

The MCM rate was calculated as [total number of live births with an MCM] + [total number of pregnancy losses with an MCM] ÷ [total number of live births] + [total number of pregnancy losses with an MCM]. Spontaneous pregnancy losses and induced abortions where no abnormalities were reported were not included for analysis as we do not know if they were examined in detail and therefore cannot know the outcome. The total numbers presented for each group are therefore either the total number of outcomes or the total number of informative outcomes—that is, excluding pregnancy losses with no abnormalities reported. Full details on study methodology have been previously reported.5

RESULTS

Through August 31, 2007, complete outcome data were available on 203 prospectively reported pregnancies that had had first trimester exposure to topiramate, of which 70 had been exposed to topiramate in monotherapy.

Pregnancy outcome details for all exposures are shown in table 1. Of all pregnancies exposed to topiramate, 178 (87.7%) resulted in a live birth. Of these, 31 pregnancies had an abnormality of some kind (17.4%; 95% CI 12.5% to 23.7%) with 16 of these being an MCM (9.0%; 95% CI 5.6% to 14.1%). Four MCMs were oral clefts (2.2%; 95% CI 0.9% to 5.6%) with three infants having both cleft lip and cleft palate. Four cases of hypospadias were reported (5.1%; 95% CI 0.2% to 10.1%) among 78 known live male births of which two were classified as major malformations. Full details on major and minor malformations are shown in tables 2 through 5.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Outcomes of pregnancies exposed to topiramate

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 Major congenital malformations with topiramate monotherapy

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 3 Minor congenital malformations with topiramate monotherapy

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 4 Major congenital malformations with topiramate polytherapy

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 5 Minor congenital malformations with topiramate polytherapy

For the three infants who had an MCM and who were exposed to topiramate in monotherapy the average total daily dose was 400 mg of topiramate compared to 238 mg in those without an MCM (p = 0.123). Of the 61 cases exposed to topiramate in monotherapy for which there was information about gestational age, six infants (9.8%) were born at 37 weeks gestation or less. The average total daily dose for those born prematurely (250 mg) was not significantly different from those born after 37 weeks (246 mg (p = 0.934). Of the 56 monotherapy outcomes for which there were full data on gestational age and birthweight, 8 (14.3%) were small for gestational age (SGA). The mean total daily dose for those who were SGA (346 mg) was not significantly different from those who were not SGA (239 mg, p = 0.084).

For polytherapy outcomes 32 combinations of at least one AED in addition to topiramate were recorded. Thirteen infants born with a major malformation were exposed on average to 342 mg per day of topiramate compared with 294 mg per day for live births without an MCM (p = 0.539). Of the 111 cases exposed to topiramate as part of a polytherapy regimen, for which there was information on gestational age, 17 infants (15.3%) were born at 37 weeks or less gestation. The mean total daily dose for those born prematurely (347 mg) was not significantly different from those born after 37 weeks (288 mg, p = 0.891). Of 103 live births exposed to topiramate as part of a polytherapy regimen and for which there were data regarding birthweight and gestational age, 20 infants (19.4%) were SGA. The mean total daily dose for those infants who were SGA (405 mg) was significantly different from those who were not SGA (260 mg, p = 0.019). We have no data on maternal weights in pregnancy.

Co-administration of valproate with topiramate either as part of a duotherapy regimen (n = 12, MCM rate 36.4%; 95% CI 15.2 to 64.6%) or as part of a regimen of three or more AEDs (n = 23, MCM rate 23.8%; 95% CI 10.6 to 45.1%) was associated with the highest rates of MCM. This compared with a lower rate of MCM for exposures not including valproate (n = 110, MCM rate 8.4%; 95% CI 4.3% to 15.8%).

DISCUSSION

The MCM rate for monotherapy exposures to topiramate was well within the range quoted for other AEDs.5 For polytherapy exposures the MCM rate was higher, consistent with previous reports comparing monotherapy and polytherapy exposures to all AEDs.3–5 The MCM rates for combinations containing valproate in addition to topiramate were higher than for combinations not containing valproate. While it is not clear if this is a consequence of an interaction between these drugs, is a reflection of unidentified patient characteristics, or is due to valproate, which has increasingly been shown to be associated with a high risk of MCMs, either in monotherapy or as part of a polytherapy regimen,5,12 is unclear. Clearly these results need to be replicated in larger numbers and from different registers before we might counsel women of child-bearing age against using combinations including topiramate and valproate.

All of the MCMs observed have already been described in pregnancies exposed to AEDs other than topiramate and no apparent dose response was evident either for monotherapy or polytherapy exposures. We found the rates of oral clefts (2.2%) and hypospadias (5.1%) much higher than that reported in the United Kingdom. For oral clefts, which occur in 1 in 500 live births in the United Kingdom,13 the observed rate was 11 times higher than the background rate. For hypospadias, which is estimated to occur in 1 in 300 live births,14 the observed rate was approximately 14 times the background rate.

The mean birthweights for live infants exposed in utero to topiramate either as monotherapy or as part of combination therapy were within the normal range with a trend to lower birth weight in polytherapy exposures. Infants who were SGA were exposed to a significantly higher daily dose of topiramate but only when exposed to topiramate as part of combination therapy. In animal studies embryotoxicity (including reduced fetal weight gain) was observed at doses as low as 0.5 times the maximum recommended human dose.9 Unfortunately we have no data on maternal weights, either before or during pregnancy, and therefore cannot comment on any potential interaction between maternal weights and the outcome of SGA.

While our results are preliminary, they are relevant not only in dealing with women with epilepsy of childbearing years. Topiramate is also licensed for use for migraine prophylaxis, an even more common condition which also occurs frequently in women of childbearing years. While the risks for adverse outcomes, including teratogenic endpoints, may differ between patient groups exposed to the same drug but used for different indications, the teratogenic potential of any agent is also likely determined by factors related to the structure and functional effects of the agent, the dose prescribed, and the timing of use. This is also likely to be the case for topiramate. Monitoring pregnancies in women with migraine exposed to topiramate should therefore be encouraged.

Footnotes

  • Disclosure: The study was made possible by a research grant from the Epilepsy Research Foundation and a number of unrestricted educational grants from pharmaceutical companies (Glaxo-Smith-Kline, Sanofi-Aventis, UCB-Pharma, Janssen-Cilag, Pfizer, Eisai). An Internet-based Web site detailing the aims of the UK Epilepsy and Pregnancy Register was made possible by a grant from Glaxo-Smith-Kline. Over the lifetime of the register, these grants have exceeded $10,000 from each company/grant awarding body. S.H., J.C., A.R., W.H.S., L.P., P.M., R.W., B.I., and J.M. have attended meetings with the support of various pharmaceutical companies, including Janssen-Cilag. J.C., L.P., P.M., and J.M. have given lectures at the bequest of pharmaceutical companies, including Janssen-Cilag, for which they have received honoraria. No individual has received personal compensation in excess of $10,000. I.R. reports no conflicts of interest.

    Received November 19, 2007. Accepted in final form April 2, 2008.

REFERENCES

  1. 1.↵
    EUROCAT Annual Report to WHO 2004-5. Available at: http://www.eurocat.ulster.ac.uk/pdf/EUROCAT-Annual-Report-2005-for-WHO.pdf. Accessed January 2008.
  2. 2.
    Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998;39:887–892.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132–1138.
    OpenUrlCrossRefPubMed
  4. 4.
    Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739–746.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193–198.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    Cunnington M, Tennis P, et al. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955–960.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006;67:1876–1879.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Meischenguiser R, D’Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004;5:163–167.
    OpenUrlCrossRefPubMed
  9. 9.↵
    FDA product characteristics (2003). Available at: http://www.fda.gov/medwatch/SAFETY/2003/03APR_PI/Topamax_PI.pdf. Accessed March 2007.
  10. 10.↵
    Kwarta RF, Hulihan JF, Schmider J, Nye JS. Pregnancy outcomes in topiramate-treated women. Epilepsia 2006;47, suppl 4:119–204. Abstract.
  11. 11.↵
    de Wals P, Mastroiacovo P, Weatherall JAC, et al., eds. EUROCAT Guide for the Registration of Congenital Anomalies. Brussels: European Union, 1984.
  12. 12.
    Vajda FJ, O’Brien TJ, Hitchcock, et al. A critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004;11:854–858.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Harper PS. Practical Genetic Counseling, 6th ed. Arnold; 2004.
  14. 14.↵
    Abdullah NA, Pearce MS, Parker L, Wilkinson JR, Jaffray B, McNally RJ. Birth prevalence of cryptorchidism and hypospadias in northern England, 1993–2000. Arch Dis Child 2007;92:576–579.
    OpenUrlAbstract/FREE Full Text

Disputes & Debates: Rapid online correspondence

  • Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register
    • María-Luisa Martínez-Frías, Professor of the Faculty of Medicine, Director of the Research Center of Congenital Anomalies (CIAC), Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Madrid, Spainmlmartinez.frias@isciii.es
    Submitted November 07, 2008
  • Reply from the authors
    • John Craig, MRCP, Royal Group of Hospitals, Belfast,, Grosvenor Road, Belfast, BT12 6BA, UKjohn.craig@belfasttrust.hscni.net
    • S. Hunt, MRCP, A. Russell, MRCP (Glasgow), J. Morrow, MD
    Submitted November 07, 2008
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Epilepsy/Seizures
  • Antiepileptic drugs
  • Clinical trials Observational study (Cohort, Case control)

Alert Me

  • Alert me when eletters are published
Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise